Japan Approves Shionogi Allergy Drug For Helping Unborns Breathe
This article was originally published in PharmAsia News
Executive SummaryJapan's health ministry agreed to cover Shionogi's betamethasone under the nation's health-insurance system. The drug has been sold in Japan since the 1960s, but only for treatment of allergies. The newly approved indication is for unborn babies to help them breathe. The approval marks the first in Japan for a treatment aimed at the not-yet-born. Shionogi markets the drug in Japan as Rinderon. (Click here for more
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Neon listed on the NASDAQ at $16 per share 18 months ago. It has now been picked up by the ambitious German biotech for just $2.18 per share, having recently ended its cancer vaccine programs and laid off a quarter of its workforce.